Orkla ASA, som er representert i styret i REC, har i dag tegnet seg
for 27 755 068 aksjer til en tegningskurs pr aksje på NOK 26,50 i
fortrinnsrettsemisjonen i REC. Elkem AS som er 100 % eiet av Orkla
ASA, har i dag tegnet seg for 39 977 689 aksjer til en tegningskurs
pr aksje på NOK 26,50 i fortrinnsrettsemisjonen i REC. Tegningen
innebærer at Orkla ASA og Elkem AS tegner seg for samtlige tildelte
tegningsretter. Ved gjennomføring av fortrinnsrettsemisjonen vil
Orkla ASA eie 108 244 768 aksjer og Elkem AS 155 912 989 aksjer i
selskapet, og således opprettholde sin samlede eierandel i REC på ca.
39,73 %.
Tegningen er gjort med visse betingelser som beskrevet i prospektet.
Orkla ASA,
Oslo, 29. juni 2009
Referanse:
Rune Helland, SVP Orkla Investor Relations,
Tel.: +4722 544411
Siv Merethe Skorpen Brekke, Orkla Investor Relations,
Tel.: +4722 544455
Informasjonen er distribuert av Hugin.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.